Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02399137
Title A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Acronym CARRIE
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merrimack Pharmaceuticals
Age Groups: adult
Covered Countries USA | GBR | ESP | DEU | CAN

No variant requirements are available.